RNA interference (RNAi) is a natural cellular process that regulates gene expression by a highly precise mechanism of sequence-directed gene silencing at the stage of translation by degrading specific messenger RNAs or blocking translation. In recent years, the use of RNAi for therapeutic applications has gained considerable momentum. It has been s...
Aim: Our purpose was to evaluate the possible effect of intravitreal ranibizumab on the fellow untreated eye with choroidal neovascularization (CNV) and subfoveal scarring associated with age-related macular degeneration (AMD). Methods: A retrospective observational study was conducted. One hundred eighty-seven ranibizumab-treated patients diagnose...
Graefe's Archive for Clinical and Experimental Ophthalmology
BackgroundRetinal angiomatous proliferation (RAP) is a distinct variant of neovascular age-related macular degeneration (AMD). The aim of this study is to evaluate the functional and anatomic outcome after intravitreal ranibizumab (Lucentis) treatment in patients with RAP.MethodsProspective study of consecutive patients with newly diagnosed or recu...
Background: To report 2 cases of large subretinal haemorrhage in 2 patients with age-related macular degeneration when the intravitreal injections were changed from bevacizumab (Avastin) to ranibizumab (Lucentis). Methods: Both patients were treated initially with intravitreal bevacizumab 1.25 mg for 4 months (4 injections) and then switched to 0.5...
Drugs & Aging
There is an active and controversial debate about the role of intravitreal bevacizumab versus approved drugs in the treatment of neovascular age-related macular degeneration (AMD). Because bevacizumab was available prior to the launch of ranibizumab, off-label use of the former became widespread and the cancer drug bevacizumab is the most commonly ...
Web of Science
La dégénérescence maculaire liée à l âge est une affection rétinienne débutant après 50 ans. Cette pathologie est progressive et dégénérative et se traduit par une baisse de la vision pouvant aboutir à la perte de la vision centrale. Les facteurs de risques sont multiples : l âge bien sur mais aussi les facteurs génétiques, le tabac, l exposition à...
RENNES1-BU Santé (352382103) / Sudoc / Sudoc / France / FR